Person:
ÇAMLI, AHMET ADİL

Loading...
Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
Organizational Unit
Job Title
First Name
AHMET ADİL
Last Name
ÇAMLI
Name
Email Address
Birth Date

Search Results

Now showing 1 - 4 of 4
  • PublicationOpen Access
    An Iron Deficiency Anemia Case That Came with Raw Rice Consumption
    (2015-02-01) ÇAMLI, AHMET ADİL; KARATOPRAK, CUMALİ; ÇETİN, GÜVEN; ZORLU, MEHMET; ALAY, MURAT; ÇAMLI, AHMET ADİL; KARATOPRAK, CUMALİ; ÇETİN, GÜVEN; ZORLU, MEHMET
    Pica is the chronic consumption of edible or nonedible materials that is thought to be caused by mental problems, pregnancy, or anemia. We wanted to report this case, which we have not seen in the literature before, of a pica patient who consumed raw rice due to iron deficiency anemia. A 26-year-old female patient was brought to the internal medicine polyclinic by her mother with complaints of consuming a bowl of raw rice (200 gr) every evening. The patient was treated with parenteral ferik hydroxide + sucrose complex (2700 mg) for 5 days. After 15 days, when she came to control her will to eat raw rice had been lost completely. As a result, the attention of doctors and family members for pica due to treatable causes, such as anemia, will prevent many probable complications.
  • PublicationMetadata only
    Evaluation of the relationship between serum apelin levels and vitamin D and mean platelet volume in diabetic patients
    (2014-09-01) Buyukaydin, BANU; Zorlu, MEHMET; Cakirca, MUSTAFA; KESGIN, Sidika; YAVUZ, Erdinc; ARDIC, Cuneyt; Camli, AHMET ADİL; CIKRIKCIOGLU, Mehmet Ali; KISKAÇ, MUHARREM; ZORLU, MEHMET; ÇAKIRCA, MUSTAFA; KARATOPRAK, CUMALİ; BÜYÜKAYDIN, BANU; ÇAMLI, AHMET ADİL
    Objectives. - It was reported that Vitamin D deficiency was associated with a greater risk of cardiometabolic diseases, obesity, impaired glucose tolerance and diabetes mellitus type 2, arterial hypertension, and dyslipidemia. Apelin is an adipocytokine suspected to have a role in skeletal muscle glucose utilization and glycemic regulation which may be a promising treatment modality for diabetes. It was recently reported that increased mean platelet volume (MPV) was emerging as an independent risk factor for thromboembolism, stroke, and myocardial infarction. In patients with diabetes, MPV was higher compared with the normal glycemic controls; in addition, it has been proposed that an increase in MPV may play a role in the micro- and macro-vascular complications related to diabetes. We postulated that deficiency in Vitamin D levels might be associated with higher MPV and lower serum apelin levels leading a further increase in insulin resistance in diabetic patients. So, we aimed to investigate Vitamin D levels, MPV and serum apelin levels in diabetic patients and their correlations between each other. Materials and method. - This is a cross-sectional study design. Seventy-eight patients with Diabetes Mellitus type 2, admitted to our outpatient clinic of internal medicine department at Bezmialem Vakif University, were included in our study. Forty-one patients were female; 37 patients were male. Serum apelin levels, fasting glucose levels, urea, creatinine, triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting serum insulin level, HbAl(c), free T3, free T4, TSH, vitamin D (25-OH Vitamin D) and complete blood counts were analyzed in all subjects. Results. - Each sex was analyzed separately. We found that a positive correlation existed between serum apelin levels and BMI in female patients. (r: 0.380, P: 0.014) There was also a significant positive correlation between MPV and HbAl, and fasting glucose levels and a negative correlation between MPV and PLT. (r: 0.377, P: 0.021; r: 0.395, P: 0.014; r: 0.401, P: 0.011; respectively) We failed to show a significant relationship between serum vitamin D levels, serum apelin levels and MPV in patients with diabetes mellitus type 2. Conclusion. - We failed to show an association between vitamin D, apelin and MPV higher volumes of which may have a role in cardiovascular complications related to diabetes by increasing platelet activation. (C) 2014 Published by Elsevier Masson SAS.
  • PublicationOpen Access
    Vaspin and lipocalin-2 levels in severe obsructive sleep apnea.
    (2014-06-01) KıSKAÇ, MUHARREM; ZORLU, MEHMET; AKKOYUNLU, MUHAMMED EMİN; KILIC, ERDEM; CAKIRCA, MUSTAFA; Karatoprak, CUMALİ; YAVUZ, E; ARDIC, C; CAMLI, AHMET ADİL; CIKRIKCIOGLU, M; KART, L; KISKAÇ, MUHARREM; ZORLU, MEHMET; AKKOYUNLU, MUHAMMED EMİN; KILIÇ, ERDEM; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; ÇAMLI, AHMET ADİL
    Background: Vaspin and lipocalin-2 are less-known recent members of adipocytokine family. There are ongoing studies investigating the role of vaspin ve lipocalin-2 in metabolic syndrome (MS). Obstructive sleep apnea syndrome (OSAS) is independently associated with an increased prevalence of MS. We aimed to measure the levels of vaspin and lipocalin-2 which are secreted from adipocytes in patients with severe OSAS and examine the relationship between these two adipocytokines and OSAS. Methods: The study consisted of two groups: severe OSAS patients with an apnea-hypopnea index (AHI) of >30/h (OSAS group, 34 subjects) and age-matched healthy volunteers with a AHI <5/h (control group, 25 subjects) Serum levels of vaspin and lipocalin-2 in these two groups were compared. Results: Serum levels of vaspin were significantly lower in OSAS group; patients with severe OSAS compared with control group; healthy volunteers (OSAS group: 0.69±0.5 vs. control group: 1.24±1.13; P=0.034). The difference between the two groups in terms of serum levels of lipocalin-2 has not reached statistical significance (OSAS group: 61.6±18.2 vs. control group: 68.5±20.1; P=0.17). Conclusions: We found that serum vaspin levels were significantly lower in patients with severe OSAS compared with healthy controls. Lipocalin-2 levels were similar. The decrease in serum vaspin levels in severe OSAS patients may be important in diagnosis and follow-up of these patients.
  • PublicationOpen Access
    Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients
    (2014-01-01) Cakirca, MUSTAFA; Soysal, Pinar; Zorlu, MEHMET; Kiskac, MUHARREM; Kanat, Mustafa; CIKRIKCIOGLU, Mehmet Ali; Karatoprak, CUMALİ; HURSITOGLU, Mehmet; Camli, AHMET ADİL; ERKOC, Reha; ABDUL-GHANI, Muhammad; ÇAKIRCA, MUSTAFA; KARATOPRAK, CUMALİ; ZORLU, MEHMET; KISKAÇ, MUHARREM; SOYSAL, PINAR; ÇAMLI, AHMET ADİL
    Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Materials and methods: A total of 68 type 2 DM patients who were on metformin were enrolled in the study. Based on the glycemic levels of patients, vildagliptin was added on to treatment in 33 patients. Patients were followed for 6 months. Serum ADMA, C-reactive protein, and fibrinogen levels were compared in groups of patients using metformin or metformin + vildagliptin, after 6 months. Results: Serum ADMA levels were found to be significantly lower in the group using vildagliptin compared to the group using metformin + vildagliptin (P<0.001). However, serum C-reactive protein and fibrinogen levels were statistically similar in the two study groups (P=0.34 and P=0.23, respectively). Conclusion: Metformin + vildagliptin treatment was observed to lower serum ADMA levels in type 2 DM patients. Our findings notwithstanding, large-scale prospective randomized controlled studies are warranted to conclude that vildagliptin provides cardiovascular protection along with diabetes regulation. Keywords: asymmetric dimethylarginine (ADMA); dipeptidyl peptidase-4 (DPP-4) inhibitor; type 2 diabetes mellitus; vildagliptin.